Luis Hidalgo, PhD, D(ABHI)
- Histocompatibility Lab Director
- Division of Transplantation
- PhD, Immunology, University of Alberta, 2005
- Diplomate - American Board of Histocompatibility and Immunogenetics, 2012
The focus of my research laboratory aims at elucidating the various mechanisms used by the human immune system to damage transplanted organs with specific focus on antibody-mediated rejection (ABMR). The immunologic understanding of ABMR that we have thus far identified points to a limited number of players. These players include donor-specific antibodies (DSA) (primarily targeting HLA), endothelial cell targets, and NK cell and monocyte effector cells working in concert to maximize their damage.
The laboratory’s projects are therefore split into two principal areas: immune effector cells in ABMR, and endothelial cell biology. The immune effector projects have a strong focus on assessing immune function of NK cells and monocytes particularly as it relates to activation through their Fc-gamma receptors. Endothelial cell studies relate to endothelial susceptibility to immune damage in ABMR and regulation of HLA surface expression. Findings within either of these areas have clinical implications as all of our studies are based on human immunology using primary cells. Our ultimate goal is to identify donor and recipient characteristics that define immunologic risk beyond the limited characteristics currently used.
Polyomavirus and cytomegalovirus infections are risk factors for grafts loss in simultaneous pancreas and kidney transplant.
Aziz F, Jorgenson MR, Parajuli S, Zhong W, Hidalgo LG, Djamali A, Mandelbrot D, Odorico J, Sollinger H, Astor BC, Mohamed MA
Transpl Infect Dis 2020 Feb 29; e13272
[PubMed ID: 32112710]
An in vitro model of antibody-mediated injury to glomerular endothelial cells: Upregulation of MHC class II and adhesion molecules.
Wilson NA, Dylewski J, Degner KR, O'Neill MA, Reese SR, Hidalgo LG, Blaine J, Panzer SE
Transpl. Immunol. 2020 Feb; 58: 101261
[PubMed ID: 31887408]
Preformed Donor-specific Antibodies Against HLA Class II and Graft Outcomes in Deceased-donor Kidney Transplantation.
Uffing A, Hidalgo LG, McMullan C, Perry J, Milford EL, Murakami N, Yeung MY, Guleria I, Wood IG, Akalin E, Azzi J, Chandraker AK, Riella LV
Transplant Direct 2019 May; 5(5): e446
[PubMed ID: 31165081]
Archetype Analysis Identifies Distinct Profiles in Renal Transplant Recipients with Transplant Glomerulopathy Associated with Allograft Survival.
Aubert O, Higgins S, Bouatou Y, Yoo D, Raynaud M, Viglietti D, Rabant M, Hidalgo L, Glotz D, Legendre C, Delahousse M, Shah N, Sis B, Campbell P, Mengel M, Jouven X, Van Huyen JD, Lefaucheur C, Loupy A
J. Am. Soc. Nephrol. 2019 04; 30(4): 625-639
[PubMed ID: 30872323]
Autoimmune Thyroid Disease in Islet Transplant Recipients Discontinuing Immunosuppression Late After Lymphodepletion.
Dunn A, Lam A, Hidalgo L, Shapiro AMJ, Senior PA
J. Clin. Endocrinol. Metab. 2019 04 01; 104(4): 1141-1147
[PubMed ID: 30398662]